GlassScriptPhysician profile
Judit Karacsonyi
NPI 1235833104
$57,879.06
in general payments reported to CMS, 2019-2025
13 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.04 · 2023: $124 · 2024: $57K · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $56K · Food and Beverage: $1,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $56,000.00 |
| Food and Beverage | $1,861.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50,587.59 | 2024-2025 | Avvigo Guidance System |
| Medtronic, INC. | $6,032.38 | 2024 | Symplicity G3, Onyx Frontier |
| Abbott Laboratories | $363.61 | 2024-2025 | Dragonfly Opstar, Gallant, Aveir |
| Abiomed | $292.26 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.73 | 2022-2025 | Jardiance |
| Penumbra, INC. | $123.55 | 2024 | Indigo System |
| Asahi Intecc USA, INC. | $60.03 | 2025 | Asahi Coronary Wires |
| Kiniksa Pharmaceuticals International, Plc | $37.80 | 2024 | Arcalyst |
| Chiesi USA, INC. | $35.38 | 2024-2025 | Kengreal |
| Novartis Pharmaceuticals Corporation | $26.44 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.47 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $21.35 | 2024 | Xarelto |
| Heartflow, INC. | $17.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judit Karacsonyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.